Korean J Head Neck Oncol.  2019 May;35(1):13-20. 10.21593/kjhno/2019.35.1.13.

Analysis of PD-L1 expression in salivary duct carcinoma with its efficacy as a tumor marker

Affiliations
  • 1Yonsei University College of Medicine, Seoul, Korea.
  • 2Department of Otorhinolaryngology, Yonsei University College of Medicine, Seoul, Korea.
  • 3Department of Pathology, Yonsei University College of Medicine, Seoul, Korea.
  • 4Department of Internal Medicine, Yonsei University College of Medicine, Seoul, Korea.
  • 5Department of Otorhinolaryngology, National Health Insurance Service Ilsan Hospital, Goyang, Korea. sha0109@nhimc.or.kr

Abstract

BACKGROUND/OBJECTIVES
Despite multiple approaches of treatments for salivary duct carcinoma, there has been a need for more successful treatment methods because of its poor prognosis. Treatment options like immunotherapy using new technologies have been attempted. Based on recent study results indicating that targeting programmed death receptors are effective in treating various cancers, this study aimed to identify the frequency of PD-L1 expression and its impact on survival rate in salivary duct carcinoma. MATERIALS #SPCHAR_X0026; METHODS: We studied 33 patients with salivary gland cancer who were available for histologic specimens. We examined the expression of PD-L1 in the tissues and analyzed the association with the survival rate and the association with various clinical parameters.
RESULTS
According to this study and review of similar studies, we discovered that the expression of PD-L1 in salivary duct carcinoma was lower than other types of cancers. The impact of PD-L1 on survival rate also showed inconsistency in salivary duct carcinoma.
CONCLUSION
Immunotherapy by PD-1/PD-L1 checkpoint blockade in salivary duct carcinoma needs further evaluation for clinical application.

Keyword

Salivary Duct Cancer; Programmed death ligand 1

MeSH Terms

Humans
Immunotherapy
Prognosis
Receptors, Death Domain
Salivary Ducts*
Salivary Gland Neoplasms
Survival Rate
Receptors, Death Domain
Full Text Links
  • KJHNO
Actions
Cited
CITED
export Copy
Close
Share
  • Twitter
  • Facebook
Similar articles
Copyright © 2022 by Korean Association of Medical Journal Editors. All rights reserved.     E-mail: koreamed@kamje.or.kr